• Explore /
  • Poster
  • / Tinengotinib (TT-00420) in combination with atezolizumab in Chinese patients (pts) with biliary tract carcinoma (BTC): Preliminary efficacy and safety results from a phase Ib/II study.

Tinengotinib (TT-00420) in combination with atezolizumab in Chinese patients (pts) with biliary tract carcinoma (BTC): Preliminary efficacy and safety results from a phase Ib/II study.

Abstract Poster

Authors

null

Panpan Zhang

Beijing Cancer Hospital, Beijing, China

Panpan Zhang , Jifang Gong , Zuoxing Niu , Ying Cheng , Jean Fan , Peng Peng , Caixia Sun , Hui Wang , Yingying Yu , Yujia Zhu , Yingtong Wu , Qing Li , Peng Huang , Frank Wu , Lin Shen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract

Track

Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05253053

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr 473)

DOI

10.1200/JCO.2024.42.3_suppl.473

Abstract #

473

Poster Bd #

B18

Abstract Disclosures

Similar Posters

First Author: John Ebben

First Author: Samuel Aaron Funt

First Author: Aaron C. Tan

First Author: Xianjun Yu